ClinVar Miner

Submissions for variant NM_000169.2(GLA):c.782G>T (p.Gly261Val) (rs869312401)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Integrated Genetics/Laboratory Corporation of America RCV000780301 SCV000917463 pathogenic Fabry disease 2018-12-28 criteria provided, single submitter clinical testing Variant summary: GLA c.782G>T (p.Gly261Val) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 178774 control chromosomes (gnomAD). c.782G>T has been reported in the literature in multiple individuals affected with Fabry Disease and hypertrophic cardiomyopathy (Wu_2018, Koulousios_2017, Walsh_2017, Alfadhel_2016, Lukas_2013). These data indicate that the variant is very likely to be associated with disease. Experimental evidence evaluating an impact on protein function showed that the variant resulted in an in vitro enzyme activity which was <10% of the wild-type and exhibited lyso-Gb3 levels were above the pathological cut-off (Lukas_2013). Based on the evidence outlined above, the variant was classified as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.